Biovica presents at the Annual Biomarkers Congress in Manchester 2018
Uppsala, Sweden, November 8, 2017. Mattias Bergqvist, VP Clinical Development at Biovica is invited to talk at the 13th Annual Biomarkers Congress 15-16 February 2018, Manchester, UK. As part of the congress Mattias will present at a free webinar on November 28, 2017.
At the conference Mattias will address how novel ways to measure cell proliferation offers new solutions to old challenges in drug development. Enhanced evaluation of drug efficacy by new assays such as DiviTum® can save development time and cost and provide key information during preclinical and clinical trials, with the aim to bring new drugs to the market faster.
The Biomarker Congress includes presentations, case studies, novel technologies and panel discussions focused on the opportunities and challenges of biomarker development.
Link for more information on the congress: https://www.biomarkers-congress.com/
To sign up for the free webinar on the 28th of November follow the link:
Biovica International is a company focused on providing liquid biomarkers for measuring cell proliferation and efficacy evaluation of novel cancer drugs. Mattias Bergqvist has global responsibility for clinical strategy and developing the clinical study program in collaboration with Biovica’s partners in the US & EU. During his more than 20 years of experience in the pharmaceutical and biotechnology industry, he has been Therapeutic Area Director, Oncology at AstraZeneca Nordics and worked in the Global Oncology Department, AstraZeneca UK. His areas of expertise include clinical study and market strategy during drug and biomarker development.
For more information:
Cecilia Driving, CFO Biovica
Tel.: +46 (0)73 125 92 47
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.
Read more: www.biovica.com